The APOBEC3C Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the human APOBEC3C gene in the 143B osteosarcoma cell line. This polyclonal population, generated through CRISPR/Cas9-mediated gene disruption, abolishes APOBEC3C protein expression, providing a defined loss-of-function model for examining the enzyme’s biological functions. The pooled knockout cells eliminate residual gene activity and avoid clonal variability, ensuring robust and reproducible experimental outcomes for a wide range of downstream applications.
The host 143B cell line is a thymidine kinase-deficient human osteosarcoma model derived from the HOS (HOS-MNNG) parental line. This aggressively malignant cell line is extensively used in metastasis research, particularly in xenograft paradigms of bone cancer dissemination. Its well-characterized growth properties and metastatic potential make it a valuable system for probing tumor cell invasion, migration, and genomic instability, as well as for evaluating therapeutic interventions targeting osteosarcoma progression.
APOBEC3C is a cytidine deaminase that edits single-stranded DNA, contributing to innate antiviral defense by hypermutating retroviral and retrotransposon DNA. It is induced by interferon-alpha/beta signaling, mediated by STAT1 and STAT2 downstream of JAK-STAT pathway components IFNAR1, JAK1, and IRF9. The protein interacts weakly with HIV-1 Vif and associates with RNA-binding proteins and APOBEC3B/G. Its activity promotes viral DNA deamination, increased mutation burden, and genomic instability, linking it to cancer mutagenesis.
In the context of osteosarcoma, APOBEC3C-mediated DNA editing may fuel mutation accumulation and genomic heterogeneity, factors that drive tumor evolution and treatment resistance. By knocking out APOBEC3C in 143B cells, researchers can dissect its specific contributions to innate immunity and cancer-associated mutagenesis, distinct from other APOBEC family members. This model enables precise evaluation of APOBEC3C-dependent effects on viral restriction, cellular mutagenesis, and osteosarcoma cell behavior, including proliferation and genomic integrity, within a clinically relevant bone cancer background.
This polyclonal knockout cell product is suitable for diverse functional studies. Typical applications include retroviral infection assays, mutation signature analysis, and genomic instability assays such as micronucleus scoring or ??H2AX immunofluorescence. Standard molecular techniques like Western blotting and RT-qPCR confirm knockout, while osteosarcoma-focused studies include proliferation and metastasis assays. For additional information or customized applications, please contact Ascent Research.
